Purchasers of AstraZeneca LP’s heartburn medication Nexium were not entitled to a new trial to their challenge of “reverse payment” agreements between AstraZeneca and Ranbaxy Pharmaceuticals that allegedly blocked the entry of a generic version of the drug, the U.S. Court of Appeals in Boston has decided. The plaintiffs’ argument that the trial court improperly limited their causation theory was rejected and the jury verdict was therefore affirmed (In re Nexium (Esomeprazole) Antitrust Litigation, November 21, 2016, Lynch, S.).

A full summary of this case has been published on Kluwer IP Law.

image_pdfimage_print

Leave a Reply

Your email address will not be published. Required fields are marked *